The 89-gene signature was used to stratify breast cancer patients in The Cancer Gene Atlas (TCGA) dataset in order to assess a clinical relevance of the gene signature identified in HER2+ tumors treated with neoadjuvant trastuzumab. This evidence concerns the gene ERBB2 and breast carcinoma.